Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.
Kongkiatkamon S, Terkawi L, Guan Y, Adema V, Hasipek M, Dombrovski T, Co M, Walter W, Awada H, Parker Y, Hutter S, Pagliuca S, Gurnari C, Rogers HJ, Meggendorfer M, Lindner DJ, Haferlach T, Visconte V, LaFramboise T, Jha BK, Maciejewski JP. Kongkiatkamon S, et al. Among authors: maciejewski jp. Leukemia. 2022 Aug;36(8):2086-2096. doi: 10.1038/s41375-022-01630-0. Epub 2022 Jun 27. Leukemia. 2022. PMID: 35761024
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. DeZern AE, et al. Blood Adv. 2023 Jul 25;7(14):3749-3759. doi: 10.1182/bloodadvances.2022008578. Blood Adv. 2023. PMID: 36947201 Free PMC article.
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.
Szpurka H, Jankowska AM, Makishima H, Bodo J, Bejanyan N, Hsi ED, Sekeres MA, Maciejewski JP. Szpurka H, et al. Among authors: maciejewski jp. Leuk Res. 2010 Aug;34(8):969-73. doi: 10.1016/j.leukres.2010.02.033. Epub 2010 Mar 23. Leuk Res. 2010. PMID: 20334914 Free PMC article.
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
Advani AS, Tiu R, Saunthararajah Y, Maciejewski J, Copelan EA, Sobecks R, Sekeres MA, Bates J, Rush ML, Tripp B, Salvado A, Noon E, Howard M, Jin T, Hsi E, Egorin MJ, Lim K, Cotta CV, Price C, Kalaycio M. Advani AS, et al. Leuk Res. 2010 Dec;34(12):1622-6. doi: 10.1016/j.leukres.2010.03.021. Epub 2010 Apr 27. Leuk Res. 2010. PMID: 20427086 Clinical Trial.
Updates in cytogenetics and molecular markers in MDS.
Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Tiu RV, et al. Among authors: maciejewski jp. Curr Hematol Malig Rep. 2011 Jun;6(2):126-35. doi: 10.1007/s11899-011-0081-2. Curr Hematol Malig Rep. 2011. PMID: 21340513 Review.
534 results